Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2025.
Financials
Financial year 2025
Mega Pharma from Sint-Jans-Molenbeek, company number BE0840972479, closed financial year 2025 with a result of € -3,891 after tax. For that financial year Mega Pharma recorded a gross margin of € 159,348 and equity of € 158,972. Compared with financial year 2024, the result moved from € 7,874 to € -3,891. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.
€ 158,972
▼ 2% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -3,891
▼ still € 7,874 profit in 2024
Profit after tax over the fiscal year.
€ 91,689
▲ 73% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 146,572.
People and assets in 2025
€ 99,490
▲ 36% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 35,409
▼ 26% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 103,236
▼ 17% vs 2024
€ 30,717 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 109,230
▲ 5% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 27,473
▲ 1% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 159,696 | € 126,325 | € 164,640 | € 159,348 | ▼ 3% |
| Profit after taxes | € 44,432 | € 9,538 | € 7,874 | € -3,891 | ▼ € 11,766 |
| Equity | € 183,451 | € 154,989 | € 162,863 | € 158,972 | ▼ 2% |
| Total debts | € 278,915 | € 370,527 | € 256,764 | € 240,710 | ▼ 6% |
| Cash | € 20,232 | € 67,636 | € 53,128 | € 91,689 | ▲ 73% |
| Retained profit | € 171,051 | € 142,589 | € 150,463 | € 146,572 | ▼ 3% |
| Dividend | € 0 | € 38,000 | € 0 | € 0 | |
| Bank debt | € 194,822 | € 207,037 | € 124,795 | € 103,236 | ▼ 17% |
| Balance sheet total | € 462,366 | € 525,516 | € 419,628 | € 399,682 | ▼ 5% |
| Employees (FTE) | 0.8 | 1 | - | - |
Key figures of Mega Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Mega Pharma?
What happened at Mega Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Corrected annual accounts filed for financial year 2025. Source: NBB ↗
- New establishment in Sint-Jans-Molenbeek. KBO
- Start of the company according to the CBE. KBO
In short
From € 44,432 profit in 2022 to € 3,891 loss in 2025.
Paid € 28,668 in corporate taxes since 2022.
Best year ever: 2022, with € 44,432 profit.
On average € 126,300 of value added per employee in 2023.
A new publication or filing at Mega Pharma? We notify you, reason included.
Follow Mega PharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Mega Pharma is Yildiz Karahisarli.
Directors
According to the 2025 annual accounts
Yildiz Karahisarli
Director
Establishments
Establishment units
Physical locations of this company
Leopold II laan 75
1080 Sint-Jans-Molenbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0840.972.479
- VAT number
- BE 0840.972.479
- Registered office
- Leopold II laan 75, 1080 Sint-Jans-Molenbeek
- Names & denominations
- Mega Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 November 2011
- Peppol
- Active · Active since 16 Jul 2026
- Activities · NACE
Detailhandel in farmaceutische producten